Yenis V. Argueta Guevara of Ropes & Gray has entered an appearance for drug developer Provention Bio and its top executives in a pending securities class action. The action, which accuses the defendants of misleading investors regarding the likelihood of FDA approval for its diabetes treatment teplizumab, was filed May 21 in New Jersey District Court by Pomerantz LLP and Bronstein, Gewirtz & Grossman. The case, assigned to U.S. District Judge Michael A. Shipp, is 3:21-cv-11613, Paxton v. Provention Bio, Inc. et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
